- Home
- IVT vs IBRX Comparison
IVT vs IBRX Comparison
Compare IVT & IBRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IVT
- IBRX
- Stock Information
- Founded
- IVT 2005
- IBRX 2014
- Country
- IVT United States
- IBRX United States
- Employees
- IVT N/A
- IBRX N/A
- Industry
- IVT Real Estate Investment Trusts
- IBRX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- IVT Real Estate
- IBRX Health Care
- Exchange
- IVT Nasdaq
- IBRX Nasdaq
- Market Cap
- IVT 2.3B
- IBRX 2.4B
- IPO Year
- IVT N/A
- IBRX N/A
- Fundamental
- Price
- IVT $27.47
- IBRX $2.47
- Analyst Decision
- IVT Buy
- IBRX Strong Buy
- Analyst Count
- IVT 5
- IBRX 5
- Target Price
- IVT $31.75
- IBRX $11.35
- AVG Volume (30 Days)
- IVT 457.4K
- IBRX 8.0M
- Earning Date
- IVT 04-30-2025
- IBRX 05-08-2025
- Dividend Yield
- IVT 3.46%
- IBRX N/A
- EPS Growth
- IVT 143.52
- IBRX N/A
- EPS
- IVT 0.19
- IBRX N/A
- Revenue
- IVT $273,974,000.00
- IBRX $14,745,000.00
- Revenue This Year
- IVT $10.90
- IBRX $621.53
- Revenue Next Year
- IVT $7.68
- IBRX $163.57
- P/E Ratio
- IVT $144.58
- IBRX N/A
- Revenue Growth
- IVT 6.14
- IBRX 2270.58
- 52 Week Low
- IVT $23.69
- IBRX $2.28
- 52 Week High
- IVT $31.65
- IBRX $10.53
- Technical
- Relative Strength Index (RSI)
- IVT 44.91
- IBRX 41.67
- Support Level
- IVT $25.77
- IBRX $2.35
- Resistance Level
- IVT $27.54
- IBRX $3.04
- Average True Range (ATR)
- IVT 1.00
- IBRX 0.28
- MACD
- IVT -0.02
- IBRX -0.02
- Stochastic Oscillator
- IVT 48.92
- IBRX 13.19
About IVT InvenTrust Properties Corp.
InvenTrust Properties Corp is the United States of America based company qualified as a REIT (Real Estate Investment Trust). It is focused on owning, leasing, redeveloping, acquiring and managing a multi-tenant retail platform. The company's wholly-owned and managed retail properties include grocery-anchored community and neighborhood centers and power centers, including those classified as necessity-based. InvenTrust operates through a single segment i.e. multi-tenant retail.
About IBRX ImmunityBio Inc.
ImmunityBio Inc is an integrated clinical-stage biotechnology company discovering, developing, and commercializing next-generation immuno- and cellular therapies that bolster the natural immune system to drive and sustain an immune response. Its platforms for the development of biologic product candidates include (i) antibody-cytokine fusion proteins, (ii) DNA, RNA, and recombinant protein vaccines, and (iii) cell therapies. Its focus includes bladder, lung, and colorectal cancers and GBM and its product candidate Anktiva is an IL-15 superagonist antibody-cytokine fusion protein. It has two geographical segments: the United States and Europe. Key revenue is generated from the United States.